Adi Diab, MD
The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab (Opdivo) demonstrated target lesion reductions of 72% for patients with advanced cancers, according to findings from the phase Ib PIVOT-02 trial presented at the 2017 SITC Annual Meeting.
The phase II portion of the study continues to enroll patients across 13 expansion cohorts. In addition to RCC, NSCLC, and melanoma, the study is now also enrolling those with urothelial carcinoma and triple-negative break cancer. The estimated completion date is October 2018 (NCT02983045).
Diab A. Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma, renal cell carcinoma and non-small cell lung cancer. Presented at: SITC 32nd Annual Meeting; National Harbor, MD; November 8-12, 2017. Session 207.7.
... to read the full story